> Detailanzeige

Vernieri, Claudio; Pusceddu, Sara; Fucà, Giovanni; Indelicato, Pietro; Centonze, Giovanni; Castagnoli, Lorenzo; Ferrari, Elisa; Ajazi, Arta; Pupa, Serenella; Casola, Stefano; Foiani, Marco; Mazzaferro, Vincenzo; Pruneri, Giancarlo; Milione, Massimo; de Braud, Filippo

Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs)

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs)
  • Beteiligte: Vernieri, Claudio; Pusceddu, Sara; Fucà, Giovanni; Indelicato, Pietro; Centonze, Giovanni; Castagnoli, Lorenzo; Ferrari, Elisa; Ajazi, Arta; Pupa, Serenella; Casola, Stefano; Foiani, Marco; Mazzaferro, Vincenzo; Pruneri, Giancarlo; Milione, Massimo; de Braud, Filippo
  • Erschienen: Wiley, 2019
  • Erschienen in: International Journal of Cancer
  • Sprache: Englisch
  • DOI: 10.1002/ijc.32042
  • ISSN: 0020-7136; 1097-0215
  • Schlagwörter: Cancer Research ; Oncology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:p>The mTOR inhibitor everolimus is effective against advanced pancreatic neuroendocrine tumors (pNETs). However, it can cause metabolic adverse events, such as hyperglycemia, hypertriglyceridemia and hypercholesterolemia. In this work we aimed at evaluating the impact of systemic and tumor lipid metabolism on everolimus efficacy. We carried out a monocentric, retrospective study to correlate plasma triglyceride and cholesterol levels with the progression free survival (PFS) of advanced pNET patients treated with everolimus. In formalin fixed, paraffin embedded (FFPE) tumor specimens, we also assessed by mRNA quantification and immunohistochemistry the expression of acetyl‐CoA carboxylase 1 (ACC1) and fatty acid synthase (FASN), two enzymes crucially involved in fatty acid biosynthesis, and we analyzed their impact on PFS. We evaluated 58 consecutive pNET patients who started everolimus between December 2006 and January 2015. Patients with higher plasma triglycerides during the first 3 months of treatment had an increased risk of disease progression (aHR 3.08, 95% CIs 1.15–8.21; <jats:italic>p</jats:italic> = 0.025). In 23 FFPE tumor specimens amenable for IHC evaluations, we found a positive correlation between ACC1 and FASN at both mRNA (<jats:italic>r</jats:italic> = 0.87, <jats:italic>p</jats:italic> = 0.00045) and protein (<jats:italic>r</jats:italic> = 0.68, <jats:italic>p</jats:italic> = 0.0004) level. Patients with higher ACC1 protein expression in metastatic lesions had significantly lower PFS when compared to patients with lower ACC1 levels (5.5 <jats:italic>vs</jats:italic>. 36 months; aHR 4.49, 95% CIs 1.08–18.72; <jats:italic>p</jats:italic> = 0.039). In conclusion, systemic and tumor lipid metabolism are associated with the PFS of everolimus‐treated patients with advanced pNETs; based on these findings, dietary and pharmacological interventions targeting lipid metabolism could improve everolimus efficacy in this patient population.</jats:p>
  • Zugangsstatus: Freier Zugang